-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On June 7, Xinhua Pharmaceuticals once again rose by the daily limit, closing at 246 yu.
As of the close, the fund of the closed order was 141 million yuan, accounting for 09% of its circulating market val.
Medicine is related to people's livelihood and heal.
In recent years, although the price reduction of centralized procurement has become the norm, this has not delayed a wave of market trends in the pharmaceutical segme.
In particular, the stock prices of some companies related to the fight against the epidemic have performed particularly well, including Xinhua Pharmaceutical, the stock has previously won the industry's high attention due to the continuation of the strong daily limit to achieve 11 consecutive boar.
So, is the stock still likely to rise in the future? Judging from the market situation of Xinhua Pharma, it started on April 26, when Xinhua Pharma issued an announcement stating that the company signed a "Strategic Cooperation Agreement" with Henan True Biotechnology .
, L.
, and True Bio agreed to Xinhua Pharma for its Manufacturers and distributors of Azvudine and other products in China and other countries agreed by both parti.
According to public information, azvudine is a new anti-AIDS drug with independent intellectual property rights in China, and it is also an oral drug under development for the new crown that has recently attracted much attenti.
On April 2 this year, the Center for Drug Evaluation of the State Food and Drug Administration showed that the information on "communication and publicity" showed that the status bar of the Class III meeting submitted by real organisms was changed from "processing" to "feedbac.
In this regard, the market generally believes that azvudine will be approved soon, and it is expected to become the first domestically produced new crown oral dr.
After the announcement, the A-shares of Xinhua Pharmaceuticals, which has a cooperative relationship with Real Biology, rose by the daily limit for several consecutive days, and the Hong Kong stock "Shandong Xinhua Pharmaceuticals" soared by 50% on April 2According to the data, Xinhua Pharmaceutical is a company listed on the Hong Kong Stock Exchange and Shenzhen Stock Exchange successive.
It is the first chemical synthesis pharmaceutical company in China with three pillar industries of chemical raw materials, pharmaceutical preparations and pharmaceutical intermediat.
Among them, raw materials and pharmaceutical preparations are the main source of income of the compa.
After years of development, Xinhua Pharma currently occupies an important market position in the field of antipyretic and analgesic drugs in Asia, as well as important domestic cardiovascular and cerebrovascular drugs, anti-infective drugs and central nervous system dru.
Dopa and other APIs are among the largest in the world, with an annual export volume of US$300 milli.
The company has successively established long-term strategic partnerships with over 100 multinational companies such as Bayer and G.
Financial data shows that the company's revenue and profits have maintained steady growth in recent years, but the growth rate has declin.
From 2019 to 2021, the company's revenue growth rate was 89%, 13% and 23%, respectively; the growth rate of net profit attributable to the parent in the same period was 149%, 3% and 2
Some analysts believe that through the cooperation with Real Bio, Xinhua Pharma may bring growth points to the company's performance and get the opportunity to reshape its valuati.
However, Xinhua Pharma also mentioned in the announcement that the strategic cooperation agreement with Real Bio is not exclusi.
Xinhua Pharma is just one of Real Bio's partne.
It is understood that in addition to Xinhua Pharmaceuticals, there are also companies such as China Resources Shuanghe and other companies that are currently cooperating with Real B.
Affected by this, the share price of China Resources Shuanghe has also continued to climb, soaring by more than 180% within 2 months, and has gained several consecutive boar.
In addition, Pfizer's Paxlovid has been approved in the country with conditions, and among the local pharmaceutical companies that are developing oral drugs for the new crown, in addition to Real Bio, there are also companies such as Junshi Bio and Kintor, which are competing with so many compani.
In the case of the track, how much Azivudine can share, and how much Xinhua Pharma can benefit from it, is currently unkno.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition
As of the close, the fund of the closed order was 141 million yuan, accounting for 09% of its circulating market val.
Medicine is related to people's livelihood and heal.
In recent years, although the price reduction of centralized procurement has become the norm, this has not delayed a wave of market trends in the pharmaceutical segme.
In particular, the stock prices of some companies related to the fight against the epidemic have performed particularly well, including Xinhua Pharmaceutical, the stock has previously won the industry's high attention due to the continuation of the strong daily limit to achieve 11 consecutive boar.
So, is the stock still likely to rise in the future? Judging from the market situation of Xinhua Pharma, it started on April 26, when Xinhua Pharma issued an announcement stating that the company signed a "Strategic Cooperation Agreement" with Henan True Biotechnology .
, L.
, and True Bio agreed to Xinhua Pharma for its Manufacturers and distributors of Azvudine and other products in China and other countries agreed by both parti.
According to public information, azvudine is a new anti-AIDS drug with independent intellectual property rights in China, and it is also an oral drug under development for the new crown that has recently attracted much attenti.
On April 2 this year, the Center for Drug Evaluation of the State Food and Drug Administration showed that the information on "communication and publicity" showed that the status bar of the Class III meeting submitted by real organisms was changed from "processing" to "feedbac.
In this regard, the market generally believes that azvudine will be approved soon, and it is expected to become the first domestically produced new crown oral dr.
After the announcement, the A-shares of Xinhua Pharmaceuticals, which has a cooperative relationship with Real Biology, rose by the daily limit for several consecutive days, and the Hong Kong stock "Shandong Xinhua Pharmaceuticals" soared by 50% on April 2According to the data, Xinhua Pharmaceutical is a company listed on the Hong Kong Stock Exchange and Shenzhen Stock Exchange successive.
It is the first chemical synthesis pharmaceutical company in China with three pillar industries of chemical raw materials, pharmaceutical preparations and pharmaceutical intermediat.
Among them, raw materials and pharmaceutical preparations are the main source of income of the compa.
After years of development, Xinhua Pharma currently occupies an important market position in the field of antipyretic and analgesic drugs in Asia, as well as important domestic cardiovascular and cerebrovascular drugs, anti-infective drugs and central nervous system dru.
Dopa and other APIs are among the largest in the world, with an annual export volume of US$300 milli.
The company has successively established long-term strategic partnerships with over 100 multinational companies such as Bayer and G.
Financial data shows that the company's revenue and profits have maintained steady growth in recent years, but the growth rate has declin.
From 2019 to 2021, the company's revenue growth rate was 89%, 13% and 23%, respectively; the growth rate of net profit attributable to the parent in the same period was 149%, 3% and 2
Some analysts believe that through the cooperation with Real Bio, Xinhua Pharma may bring growth points to the company's performance and get the opportunity to reshape its valuati.
However, Xinhua Pharma also mentioned in the announcement that the strategic cooperation agreement with Real Bio is not exclusi.
Xinhua Pharma is just one of Real Bio's partne.
It is understood that in addition to Xinhua Pharmaceuticals, there are also companies such as China Resources Shuanghe and other companies that are currently cooperating with Real B.
Affected by this, the share price of China Resources Shuanghe has also continued to climb, soaring by more than 180% within 2 months, and has gained several consecutive boar.
In addition, Pfizer's Paxlovid has been approved in the country with conditions, and among the local pharmaceutical companies that are developing oral drugs for the new crown, in addition to Real Bio, there are also companies such as Junshi Bio and Kintor, which are competing with so many compani.
In the case of the track, how much Azivudine can share, and how much Xinhua Pharma can benefit from it, is currently unkno.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition
